Совершенствование глюкокортикоидной терапии истинной акантолитической пызырчатки с учетом оценки функционального состояния гипофиз-надпочечники и цитокинового профиля
Диссертация
Снижение малых доз СГК до минимальной поддерживающей рекомендуется проводить по схеме, согласно которой один день в неделю доза СГК снижается на ЛА таблетки, т. е. в. течение недели всего один день больной получает дозу, уменьшенную на Ул таблетки, с последующим возвращением к предыдущей дозе. В каждую последующую неделю кратность увеличивается на один день. Такое плавное снижение дозы позволяет… Читать ещё >
Список литературы
- Ашмарин Ю.Я., Буров Г. П., Жгун A.A. О сочетании вульгарной пузырчатки и рака желудка. Клин. Мед. 1959. № 4. С.142−144.
- Белецкая Л.В., Махнева Н. В. Меченые антитела в нормальной и патологической морфологии (атлас). М., МНПИ, 2000, С. 14−18.
- Булаева H.H., Духанин A.C., Сергеев П. В., Строев Е. А. и соавт. Регуляция кальциевого обмена в лимфобластах костного мозга человека. Роль pH. Докл-АН. 1994, т.334,№ 6, С.780−781.
- Булаева H.H., Сергеев П. В., Духанин A.C. Влияние Дексаа на Са^-ответ лимфобластов при остром лейкозе. Вопр.Онкол., 1994, -3, С.36−37.
- Гончаров Н.П., Кация Г. В., Нижник А. Н. Формула жизни. Дегидроэпиандростерон: свойства, метаболизм. Биологическое значение. М., 2004.
- Гуковская A.C., Зинченко В. П. Механизмы индуцированного митогенами повышения концентрации Ca в цитоплазме тимоцитов крысы. Роль внутриклеточного pH. Биол. мембраны.- 1986.- т. З, N9.-с.920−930.
- Дедов И.И., Мельниченко Г. А., Фадеев В. В. Эндокринология. М., Медицина. 2002. С.245−251.
- Демьянов A.B., Котов А. Ю., Симбирцев A.C. Диагностическая ценность исследования уровней цитокинов в клинической практике. Цитокины и воспаление, 2003, Т.2, № 3, С.20−30.
- Духанин A.C., Ерина Т. А., Булаева H.H. и соавт. Взаимодействие глюкокортикоидов с рецепторами лимфобластов костного мозга при остром лейкозе. Бюлл.экспер.биол., 1993, № 2, С.164−165.
- Духанин A.C., Булаева H.H., Кушлинский Н. Е. и соавт. Исследование Са^-ответа лимфобластов костного мозга при остром лейкозе. Вест.онкол.науч.центра., 1993, № 5, С.24−25.
- Духанин АС, Булаева H.H. Исследование влияния кортизола на содержание кальция в лимфоцитах больных бронхиальной астмой. Бюлл.экспер.биол., 1992, № 9, С.282−284
- Добрецов Г. Е. Флуоресцентные зонды в исследовании клеток, мембран, и липопротеинов. М.- Наука.-1989.
- Европейское руководство по лечению дерматологических болезней. Под редакцией Кацамбаса А. Д., Лотти Т. М. Пузырчатка вульгарная. Ruocco V, Brenner S, Ruocco E. Москва, «МЕДпресс-информ», 2009, C.409−421.
- Карташева В.И., Шарипов А. М., Федоров A.A. и соавт. Результаты пульс-терапии преднизолоном у детей с СКВ. Педиатрия, 1989№ 2 с. 5762.
- Кетлинский С.А. Роль Т-хелперов типов и 2 в регуляции*клеточного и гуморального иммунитета. Иммунология, 2002, № 2, С.77−79.
- Кожные и венерические болезни. Руководство для врачей под редакцией Ю. К. Скрипкина, В. Н. Мордовцева. Глава 3. Дерматозы пузырные. Беренбейн Б. А., Самсонов В. А. Москва, «Медицина», 1999: с 247−241.
- Кожные и венерические болезни. Справочник под редакцией О.Л.' Иванова. Москва, «Медицина», 1997. с. 231−236.
- Лейси А. Флюорохромы./ В кн. Световая микроскопия в биологии. -М.:Мир, 1992″. С. 235.
- Лыкова С.Г. Морфогенез, клинические особенности и некоторые аспекты дифференциальной диагностики истинной акантолитической пузырчатки. Новосибирск, 1996. с. 1−84
- Лыкова С.Г., Решетникова Т. Б., Спицина A.B. ИАП: патогенетические механизмы и особенности кортикостероидной терапии. Сибирский журнал дерматологии и венерологии. 2001, № 1, С.9−13.
- Мадиевская Н.Н. Биохимические показатели гомеостаза у больных пузырчаткой, красной волчанкой, экземой и псориазом. Автореф.докт.дисс., Харьков, 1975.
- Матушевская Е.В., Кубанова А. А., Самсонов В. А. и соавт. Аутоантитела и аутоантигены при пузырчатке и пемфигоиде. Вестник дерматологии и венерологии. 1995, с.28−32.
- Матушевская Е.В., Свирщевская Е. В., Кубанова А. А. с соавт. Изучение фенотипа и функции Т-клеток больных вульгарной пузырчаткой при лечении сандимуном и глюкокортикоидами. Вестник дерматологии и венерологии. 1995, № 6, с.6−11.
- Матушевская Е.В. Пемфигус. Русский медицинский журнал, 1997. т.5,№ 11, с. 701−713
- Матушевская Е.В., Свирщевская Е. В., Дзуциева И. Р. с соавт. Изменение уровня антител к десмоглеину-3 в сыворотке крови больных пузырчатки до и после лечения. Вестник дерматологии и венерологии, 2005, № 6, С.10−14.
- Матушевская! Е.В., Лысенко А. А., Свирщевская Е. В. Клинические особенности и иммунные механизмы патогенеза истинной пузырчатки: Современные проблемы дерматовенерологии, иммунологии и врачебной косметологии. 2006. № 1. С.18−26.
- Маянский А.Н., Маянский Н. А., Заславская М. И. Нуклеарный фактор -кВ и воспаление. Цитокины и воспаление. 2007, Т.6, № 2, С.3−9.
- Махнева Н.В., Молочков В. А., Билецкая Л. В. Медикаментозная пузырчатка // Российский журнал кожных и венерических болезней. -2004. № 3. -С.14−181
- Махнева Н.В. Симптом Никольского в клинике аутоиммунных дерматозов // Российсий журная кожных и венерических болезней. -2008. № 5. — С.26−29.
- Никольский П.В. Случай pemphigus foliaceus Cazenave’a. Труды V Пироговского съезда русских врачей. 1895. С. 126−130. '
- Орлов С. Н. Кальмодулин // Итоги науки* и техники. Сер. Общие проблемы физико-химической биологии. 1987. Т. 8.
- Павлов С.Т., Самцов В. И. Классификация и дифференциальный диагноз буллезных поражений кожи. Труды Y Всесоюзного съезда дерматовенерологов. Медгиз, Ленинградское отделение. 1961, С. 103−110.
- Плейфер Дж. Наглядная иммунология. Москва. Гэотар Медицина. 2000. С.52−53.
- Потекаев Н.С., Кечкер В. И., Николаева Л. П. Злокачественные новообразования и везикуло-буллезные дерматозы. Труды 1 ММИ, т.31, Гистохимические и биохимические исследования в дерматологии -1964. С.227−232.
- Пузырные дерматозы. Псориаз. Современные методы лечения. Под редакцией Е. В. Соколовского, СОТИС, Санкт-Петербург, 1999. сЗ-48.
- Решетникова Т.Б., Начаров Ю. В. Влияние кортикостероидной терапии на цитокиновый статус у больных истинной акантолитической пузырчаткой. Сиб. журнал дерматол. и венерол. 2005 — № 6. — С.22−24.
- Романенко К.В. Хронические пузырные дерматозы. Дерматология. Косметология. Сексопатология. 2005- 3−4(8): С.149−157.
- Руководство по дермато-венерологии под ред. Л. Н. Машкиллейсона, 1964, т. З, С.286−324.
- Сергеев П.В., Галенко-Ярошевский П.А., Ханкоева А. И., Духанин A.C. Изучение механизма действия бефола на кальциевый обмен в кардиомиоцитах с помощью флуоресцентного зонда «ФУРА-2″.Бюлл. Экспер. Биол. 1996, № 3, С.288−291.
- Сергеев-'ILBl,. Шимановский HJt Духанин: A.C. Роль* мембранотропных эффектов глюкокортикоидов в реализации» их фармакологической активности (обзор). Бюлл. экспер. биол., 2002, т.134, № 9. С.244−253.
- Свирщевская Е.В., Вискова Н. Ю., ЧудновскаяТ.Н., Гурина О. Н., Матушсвская Е. В: Участие Т-хелперов 2-го типа- в патогенезе аутоиммушой'-<�пузырчатки.' Иммунология^ 2002-.№ 2-.Gi .M-241−15i-
- Страчунский Л: С., Козлов С. Н. Глюкокортикоидные препараты: г. Смоленск, 1997, С. 5-И,
- Торсуев H.A., Шеклаков- Н.Д., Романенко В. Н. Буллезные дерматозы. «Медицина», Москва, 1979.
- Фицпатрик Т., Джонсон Р., Вулф К. и соавт. Дерматология. Vc Graw-НШ'Пракшка. 1999. С. 409−413.
- Цурова З.С. Клеточные механизмы патогенеза истинной пузырчатки. Вестник дерматологии и венерологии. 1997. № 5, С. 15−18.
- Aberer W., Wolff-Schreiner EC, Stingl G, Wolff K. Asathioprine in treatment of pemphigus vulgaris. J Am Acad Dermatol., 1987- 16: 527−33.
- Akerman L, Mimouni D, David M. Intravenous immunoglobulin for treatment of pemphigus. Clin Rev Allergy Immunol., 2005- 29(3): 289−94.
- Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile: J. Am. AcadrDermatoU, 1999- 40(2Pt l): 167−70:
- Amagai M-:Tsunoda K, Suzuki H, Nishifuji K, Koyasu S, Nishikawa T. Use of autoantigen-knockout mice in developing an: active autoimmune disease model for pemphigus. J Clin Invest 2000- 105:625−631.
- Anhalt G.J. Paraneoplastic pemphigus. Adv. Dermatol-, 1997: 12: 77−96.
- Anhalt G.R. Paranaoplastic pemphigus: the role of tumors and drugs. Br J Dermatol., 2001- 144: 1101−4.
- Angelini G, Bonamonte D, Lucchese A, Favia G, Serpico R, Mittelman A, Simone S, Sinlia AA, Kanduc D. Preliminary data on Pemphigus vulgaris treatment by a proteomics-deflned peptide: a case report. J Transl Med., 2006, 24- 4:43-.
- Antonucci A, Negosanti M, Tabanelli M- et al. Treatment' of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases. J Dermatolog Treat., 2007- 18(3): 178−83.
- Arranz D, Corral M, Prats I et1 ah Herpetiform pemphigus-associated with' esophageal carcinoma. [Article in Spanish]. Actas Dermosifiliogr., 2005- 96(2): 119−21.
- Ashraf O, Sharif H. Pulmonary embolism in pemphigus vulgaris, the need for judicious immunotherapy. J Pak Med3 Assoc., 2005- 55(7): 306−8:
- Asilian A., Yoosefi A, Faghini G. Pemphigus vulgaris in lran: epidemiology and clinical profile. Skinmed., 2006- 5(2): 69−71.
- Baroni A., Perfetto B-, Ruocco E. et all Cytokine pattern-inblister fluid and- sera of patients with pemphigus. Dermatology, 2002- 205(2): 116−21.
- Baum S, Scope A, Barzilai A', Azizi E, Trau №. The role of. IVIg treatment in severe pemphigus vulgaris. J Eur Acad Dermatol Venereol., 2006- 20(5): 548−52.
- Beesley AH, Weller RE, Senanayake S, Welch M et al. Receptor mutation is not a common mechanism of naturally occurring glucocorticoid resistance in leukaemia cell lines. Leuk Res., 2008- 11: 345−348.
- Bhol KC., Rojas Ali, KhamlU. et-alLPresence of interleukin 10 in the serums and blister fluid- of patients with- pemphigus- vulgaris: andi pemphigoid: Cytokine., 2000- 12(7): 1076−83.
- Bordel-Gomezi MT- Sanchez-EstellavJi Yuste-Chaves Mf et al: Familial pemphigus vulgaris: immunogenetic study of HLA class II antigens. [Article in Spanish] Actas Dcrmosifiliogr., 2006: 97(8): 509−13.
- Bouloc A., Joly P. Saint-Leger E. et al. Paraneoplastic pemphigus with circulating antibodies directed exclusively against the pemphigus vulgaris antigen desmoglein 3. JAmAcadDermatol., 2000- 43:714−7.
- Bowen GM, Peters NT, Fivenson DP, et al. Lichenoid dermatitis im paraneoplastic pemphigus: a pathogenic trigger, of epitope spreading? Arch Dermatol. 2000: 136: 652−656.
- Bronmmann M., von Feibert V., Streit M. et all. Progressive respiratory failure in paranaoplastic pemphigus associated with chronic lymphocytic- leukemia- Dermatology, 2004- 208: 251−4-
- Bystiyn JC, Stemman NM. The adjuvant therapy of pemphigus Arch Dermatol., 1996- 132: 203−212.
- Calcagni E., Elenkov I. Stress system activity, innate and T helper cytokines, and susceptibility to immune-related disease. Ann N Y Acad Sei., 2006- 106 962−76.
- Camisa C., Helm T.N., Liu Y.C. et al. Paraneoplastic pemphigus: a report of three cases including one long-term survivor. J. Am. Acad. Dermatol., 1992- 27: 547−553.
- Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Arch Dermatol., 1993- 129: 883−886.
- Challacombe SJ, Setterfield J, Shirlaw P, Harman K et al. Immunodiagnosis of pemphigus and mucous membrane pemphigoid. Acta Odontol Scand., 2001- 59(4): 226−34.
- Cohen MA, Cohen JJ, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in pemphigus foliaceus. Int J Dermatol., 2002- 41: 340−4.
- Cotell S., MD, Robinson N.D., MD., Chan LS., MD. Autoimmune Blistering Skin Diseases. Am. J. Emerg. Med., 2000- 18: 288−299.
- Cremniter D., Baudin M., Roujeau J-C. et all. Stressful life events as potential triggers of pemphigus. Arch.Dermatol., 1998- 134:1486−1487.
- Cummins DL, Mimouni D, Tzu J et al. Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies. J Am Acad Dermatol., 2007- 56(1): 153−9.
- Da Silva K, Mandel L. Early manifestation of pemphigus vulgaris. A case report. N Y State Dent J., 2007- 73(3): 42−4.
- Daoud Y. J., Cervantes R, Foster C. S et al. Ocular pemphigus. J Am Acad Dermatol., 2005- 53: 585−90.
- David M, Katzenelson V, Mimouni D. et al. The distribution of pemphigus vulgaris-IgG subclasses in patients with active disease. J Eur Acad Dermatol Venereol., 2004- 18(2): 241−2.
- De la Torre B., Fransson J., Scheynius A. Blood dehydroepiandrosterone sulphate (DHEAS) levels in pemphigoid/pemphigus and psoriasis. Clin Exp Rheumatol., 1995- 13(3): 345−8.
- Dmochowski M, Hashimoto-T, Nishikawa T The analysis of IgG subclasses of anti-intercellular antibodies in pemphigus by an immunoblot technique. Arch-Dermatol Res., 1992- 284: 309−311.
- Dos Reis VM, Cuce LC, Rivittin EA. Anatomopatology and direct and indirect immunofluorescence of lesions of endemic pemphigus foliaceus resistent to corticoid therapy. Rev Inst Med Trop Sao Pulo., 1991- 33(2): 97 103.
- Duparc A, Boivin S, Gilbert D et al. Paraneoplastic pemphigus with pemphigus vegetans-like lesions revealing. non-Hodgkin lymphoma. Eur J DermatoL, 2006- 16(6): 698−9.
- Dupuy A, Viguier M, Bedane C, et al: Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol., 2004- 140: 91−6.
- El Tal AK, Posner MR, Spigelman Z, Ahmed AR. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. J Am Acad Dermatol., 2006- 55(3): 449−59.
- Elenkov IJ. Glucocorticoids and the ThlTh2 balance. Ann N Y Acad Sei., 2004- 1024: 138−46.
- Elder David E., Elenitsas R., Johnson B., Ioffreda M. et all. Histopathology of the skin. Wolter Kluver. Lippincott. Williams and Wilkins. 2007- 166−183.
- Eming R, Budinger L, Riechers R et al. Br. J. Dermatol, Frequency analisys of autoreactive T-helper 1 and 2 cells in bullous pemphigoid and pemphigus vulgaris by ensyme-linked immunospot assay. Br J Dermatol., 2000- 143(6): 1279−82.
- Espana A, Fernandez S, del Olmo J, Marquina M, Pretel M, Ruba D, Sanchez-Ibarrola A. Ear, nose and throat manifestations in pemphigus vulgaris. Br J Dermatol., 2007- 156(4): 733−7.
- Esposito M, Capriotti E, Giunta A, Bianchi L, Chimenti S. Long-lasting remission of pemphigus vulgaris treated with rituximab. Acta Derm Venereol., 2006- 86(1): 87−9.
- Faghihi G., Radan M. Paraneoplastic pemphigus with clinical features of lichen planus associated with B cell lymphoma. Abstract from CD. J Eur Acad Dermatol Venereol, 2008- FP0149.
- Fardet L., Flahault F., Kettaneh A., Tiev K.P. et all. Corticosteroid-induced clinical adverse events: frequency, risk factor and patient, s opinion. Br J Dermatol., 2007.- 157: 142−148.
- Fatourechi MM, el-Azhary RA, Gibson LE. Rituximab: applications in dermatology. Int J Dermatol., 2006- 45(10): 1143−55
- Feliciani C., Toto P., Amerio P.A. et al. In vitro C3 mRNA expression in pemphigus vulgaris: complement activation is oncreased by IL-la and TNF-a. J. Cutan. Med. Surg., 1999- 3(3): 140−4.
- Fenniche S, Benmously R, Marrak H et al. Neonatal pemphigus vulgaris in an infant born to a mother with pemphigus vulgaris in remission. Pediatr Dermatol., 2006- 23(2): 124−7.
- Fleischli ME, Valek RH, Pandya AG. Pulse intravenous cyclophosphamide therapy in pemphigus. Arch Dermatol., 1999- 135(1): 57−61.
- Frost N, Messer G, Fierlbeck G, Risler T, Lytton SD. Treatment of pemphigus vulgaris with protein A immunoadsorption: case report of longterm history showing favorable outcome. Ann N Y Acad Sei., 2005- 1051: 591−6.
- Fullerton S.H., Woodley D.T., Smoller B.R., Anhalt G.J. Paraneoplastic pemphigus with autoantibody deposition in bronchial epithelium after autologous bone marrow transplantation. J Am Med., 1992- 267: 1500−1502.
- Futei Y, Amagai M, Ishii K. et al. Predominant IgG4 subclass in autoantibodies, of pemphigus vulgaris and foliaceus. J Dermatol., 2001- 26: 55−61.
- Fukuda S., Mitsuoka H., Schmidt-Schonbein GW. Leukocyte fluid' shear response in the presence of glucocorticoid. J Leukoc Biol., 2004- 75(4): 66 470.
- GeevasingaN, Wallman L, Katelaris CH. Mycophenolate mofetil- a review of indications and use in a large tertiary hospital. Iran J Allergy Asthma Immunol., 2005- 4(4): 159−66.
- Giesecke E, Enk A, Kerstin S. Treatment of pemphigus vulgaris with highdose intravenous immunoglobulins in a patient with steroid-induced osteonecrosis of the femoral head. [Article in German] J Dtsch Dermatol" Ges., 2004- 2(5): 354−6.
- Goebeler M, Herzog S, Brocker EB, Zillikens D. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol., 2003- 149: 899−901.
- Goh MS, McCormack C, Dinh HV et al. Rituximab, in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br J Dermatol., 2007- 156(5): 990−6.
- Gokhale NR, Mahajan PM, Sule RR et al. Treatment of pemphigus with intravenous pulse cyclophosphamide. Indian J Dermatol Venereol Leprol., 2003- 69(5): 334−7.
- Gouveia C.F., Coutinho V., Filipe P., Cirue-de-Castro S.L. Morbidity and mortality from steroid therapy in pemphigus. JAAD, 2004, 2, 50, № 3.
- Grando SA, Glukhenky BT, Drannik GN et al. Mediators of inflamation in blister fluids from patients with pemphigus vulgaris and bullous pemphigoid. Arch. Dermatol., 1989- 125(7): 925−30.
- Gross KL, Lu NZ, Cidlowski JA. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol., 2008- 19: 345−350
- Gupta R. Prolonged remission of pemphigus induced by dexamethasone-cyclophosphamide pulse therapy. Indian J Dermatol Venereol Leprol., 2007- 73(2): 121−2.
- Hacker MK, Janson M, Fairley JA, Lin MS Isotypes and antigenic pro Wies of pemphigus foliaceus and pemphigus vulgaris autoantibodies. Clin Immunol., 2002- 105: 64−74.
- Hacker-Foegen MK, Janson M, Amagai M, Fairley JA, Lin MS. Pathogenicity and epitope characteristics of antidesmoglein-1 from pemphigus foliaceus patients expressing only IgGl autoantibodies. J Invest Dermatol., 2003, 121: 1373−1378.
- Hahn K, Kippes W, Amagai M, Rzany B. et al. Clinical aspects and immunopathology in 48 patients with pemphigus. [Article in German]'. Hautarzt, 2000- 51 (9): 670−7.
- Hallaji Z, Esmaeeli N, Chams Davachi C et al. Prognostic factors of pemphigus vulgaris. Abstract from CD. J Eur Acad Dermatol Venereol., 2008- FP0155.
- Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol., 2006- 33(2): 230−9.
- Handjani F, Shahbazi. Clinical features of 150 patients with pemphigus in southern Iran. Eur Acad Derm Venereol., 2004- 18 (Suppl.2): 179.
- Harman KE, Albert S, Black MM, British Association of Dermatologists. Guidelines for the management of pemphigus vulgaris. Br J Dermatol., 2003- 149: 926−37.
- Hashimoto T. Recent advances in the study of the pathophysiology of pemphigus. Achives of dermatological recearch., 2003- 295: 2−11.
- Heathers GP, Evers AS, Corr PB. Enhanced inositol trisphosphate response to alpha 1-adrenergic stimulation in cardiac myocytes exposed to hypoxia. J Clin Invest., 1989- 83(4): 1409−13.
- Herbs A., Bystryn S.-C, Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol., 2000- 42: 422−427.
- Hertl M, Eming R, Borradori L. Rituximab (anti-CD20 monoclonal antibody)~ultimate or first choice in pemphigus? Dermatology., 2007- 214(4): 275−7.
- Hertl M, Veldman C. T-cellular autoimmunity against desmogleins in pemphigus, and autoantibody-mediated bullous disorder of the skin. Autoimmun. Rev., 2003- 2(5): 278−83.
- Hoareau F, Croue A, Marchetta X et al. Pemphigus vulgaris and" intraepithelial neoplasia localized to the vagina. [Article in French]. Ann Dermatol Venereol, 2007- 134(6): 564−6.
- Hoque SR, Black MM- Cliff-S. Paraneoplastic pemphigus associated with CD20-positive follicular non-Hodgkin's lymphoma treated with rituximab: a third case resistant to rituximab therapy. Clin Exp Dermatol., 2007- 32(2): 172−5.
- Hulleman E, Kazemier KM, Holleman A, Vanderweele DJ et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood., 2008- 31: 3421−3426.
- Imataki O, Tamai Y, Abe Y et al. A case of follicular lymphoma complicated with lethal pemphigus. [Article in Japanese]. Gan To Kagaku Ryoho., 2006- 33(11): 1677−80.
- Iranzo P, Alsina M, Martinez-De Pablo I et al. Gold: an old drug still working in refractory pemphigus. J Eur Acad Dermatol Venereol., 2007- 21(7): 902−7.
- Jamora MJ, Jiao D, Bystryn JC. Antibodies to desmoglein 1 and 3, and the clinical phenotype of pemphigus vulgaris. J Am Acad Dermatol., 2003- 48: 976−7.
- Jablonska S., Chorzelski T., Beutner EH et all. Herpetiform pemphigus, a variable pattern of pemphigus. Int J Dermatol., 1975- 14: 353−359.
- Jardin F, Levesque H, Tilly H. et al. Auto-immune manifestations in Non-Hodgkin's lymphoma. [Article in French]. Rev Med Interne., 2005- 26(7): 557−71.
- Joly P, D’Incan M, Musette P. Rituximab for pemphigus vulgaris. N Engl J Med., 2007- 356(5): 521−2.
- Joly P., MD, Richard C., MD, Gilbert D., MD et all. Sensitivity and specificity of clinical, histologic and immunologic features in the diagnosis of paraneoplastic pemphigus. J. of the Amer. Acad, of Dermatol., 2000- 43(4): 619−626.
- Kahawita IP, Fernando MS, Sirimanna GM et al. Paraneoplastic pemphigus associated with inflammatory myofibroblastic tumor. Int J Dermatol., 2006- 45(11): 1394−6.
- Kaiser J, Kaatz M, Eisner P, Ziemer M. Complete remission of drug-resistant Pemphigus vegetans treated by extracorporeal photopheresis. J Eur Acad Dermatol Venereol., 2007- 21(6): 843−4.
- Kalish R.S. Pemphigus vulgaris: the other half of the story. The journal of Clinical Investigation, 2000- 106 (12): 1433−1435.
- Kallel Seilami M, Ben Ayed M, Mouquet H et al. Anti-desmoglein 1 antibodies in Tunisian healthy subjects: arguments for the role of environmental factors in the occurrence of Tunisian pemphigus foliaceus. Clin Exp Immunol., 2004−137:195−200.
- Kanwar A, Saudipan D. Factors responsible for death in patients with pemphigus. J dermatol., 1994- 21: 655−9.
- Kanwar AJ, Ajith AC, Narang T Pemphigus in North India. J Cutan Med Surg., 2006- 10(1): 21−5.
- Kaplan Y., Hodak E,. Ackerman L. et all. Neoplasms associated with paranaoplastic pemphigus: a review with emphesis on non-hematologic malignancy and oral mucosal manifestation. Oral Oncol., 2004- 40: 553−62.
- Kawashita MY, Tsai K, Aoki V, Santi CG, et all. Mycophenolate mofetil as an adjuvant therapy for classic and endemic pemphigus foliaceus. J Dermatol., 2005- 32(7): 574−80.
- Kim S.C., Kwon Y.D., Lee Y.J. et all. CDNA cloning of the 210 paraneoplastic pemphigus antigen revels that envoplakin is component of the antigen complex. J Invest Dermatol., 1997- 109: 365−9.
- Kino-T., De MartinO’MU., Charmandari E. et al. Tissue glucocorticoid resistancehypersensitivity syndroms. J Steroid Biochem Mol Biol., 2003- 85(2−5): 457−67.
- Korman MJ. New and emerging therapies in the treatment a blistering diseases. Dermatology Clinics, 2000- 18: 127−137.
- Kottke MD, Delva E, Kowalczyk AP. The desmosome: cell science lessons from human diseases. J Cell Sei., 2006- 119: 797−806.
- Krain L.S., MD, Bierman S.M., MD. Pemphigus vulgaris and internal malignancy. Cancer, 1974- 33: 1091−1099.
- Kricheli D, David M, Frusic-Zlotkin M, et al. The distribution of pemphigus vulgaris-IgG subclasses and their reactivity with desmoglein 3 and 1 in pemphigus patients and their Wrst-degree relatives (see comments). Br J Dermatol., 2000- 143: 337−342.
- Kuitunen T, Malmstrom J, Palva E et al. Pancytopenia induced by low-dose methotrexate. A study of the cases reported to the Finnish Adverse Drug Reaction Register From 1991 to 1999. Scand J Rheumatol., 2005- 34(3): 23 841.
- Kumrah L., Ramam M, ShahP, Panday RM, Pasricha JS. Pituitary-adrenal function following dexamethasone-cyclophosphamide pulse therapy for pemphigus. Br J> Dermatol., 2001- 145(6): 944−8.
- Kurokawa M, Koketsu H, Oda Y A case of pemphigus vulgaris accompanied by multiple myeloma. Int J Dermatol., 2005- 44(10): 873−5.
- Lam S., Stone M.S., Goeken J.A., Massicotte S.J. et al. Paraneoplastic pemphigus, cicatricial conjunctivitis, and acanthosis nigricans with pachydermatoglyphy in a patient with bronchogenic squamous cell carcinoma. Ophthalmology, 1992- 99: 108−113.
- Lane J.E.- Woody C, Davis L.S. et al. Paraneoplastic Autoimmune Multiorgan Syndrome (Paraneoplastic Pemphigus) in a Child: Case Report and Review of the Literature. Pediatrics, 2004- 114: 513−516.
- Lange D, Meiss F, Fiedler E et al. Gold. Effective therapy for mucosal lesions of pemphigus vulgaris. [Article in German]. Hautarzt, 2007- 58(2): 142−5.
- Lee JS, Kim Soo-Chan, Kim Hee Sung, et al. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma arising from Castleman’s tumor J. of the Amer. Acad, of Dermatol., 1999- 40(2): 294−297.
- Lee JS, Pei-Lin Ng P, Tao M, Lim WT. Paraneoplastic pemphigus resembling linear IgA bullous dermatosis. Int J Dermatol., 2006- 45(9): 10 935.
- Lever WF, Schaumburg-Lever G. Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982. Arch Dermatol., 1984- 120(1): 44−7.
- Li N, Aoki V, Hans-Filho G, Rivitti EA, Diaz LA. The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo seivagem). J Exp Med., 2003- 197: 1501−1510
- Li W, Feng Y, Lu XY et al. Gene fragments cloned and immune recognition studied preliminarily for desmoglein 4 in pemphigus vulgaris. [Article in Chinese]. Sichuan Da Xue Xue Bao Yi Xue Ban., 2007- 38(1): 84−7.
- Lippman ME, Dickson RR, Gelmann EP et al. Grouth regulatory peptide production by human brest carcinoma cells. J Steroid Biochem, 1978- 30: 5361.
- Lombard! ML, Mercuro O, Ruocco V et al. Common human leukocyte antigen alleles in pemphigus vulgaris and pemphigus foliaceus Italian patients. J Invest Dermatol, 1999- 113: 107−10.
- Machler V., Antoni С., Ahalt G.J. et al. Graft-versus-host-like mucocutaneus eruptions with serological features of paranaoplastic pemphigus and systemic lupus erythematosus in a patient with non-hodgcin lymphoma. Dermatology, 1998- 197: 78−83.
- Martinez De Pablo MI, Iranzo P et al. Paraneoplastic pemphigus associated with non-Hodgkin B-cell lymphoma and good response to prednisone. Acta Derm Venereol., 2005- 85(3): 233−5.
- Maruyama H, Kawachi Y, Fujisawa Y et al. IgA/IgG pemphigus positive for anti-desmoglein 1 autoantibody. Eur J Dermatol., 2007- 17(1): 94−5.
- Maruani A., Machet M., Carlotti A. Immunostaining with antibodies to desmoglein allows to predict the jutcome of drug-induced pemphigus. Abstract from CD. J Eur Acad Dermatol Venereol., 2008- FP0416.
- Marzano AV, Vezzoli P, Mariotti F et al. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma and Castleman disease. Br J Dermatol., 2005- 153(1): 214−5.
- Marzano AV, Fanoni D, Venegoni L et al. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Dermatology, 2007- 214(4): 310−8.
- Marzano AY, Tourlaki A, Cozzani E et al. Pemphigus herpetiformis associated with prostate cancer. J Eur Acad Dermatol Venereol., 2007- 21(5): 696−8.
- Masood Q, Hassan I, Majid I et al. Dexamethasone cyclophosphamide pulse therapy in pemphigus: experience in Kashmir valley. Indian J Dermatol Venereol Leprol., 2003- 69(2): 97−9.
- Menenakos C, Braumann C, Hartmann J et al. Retroperitoneal Castleman’s tumor and paraneoplastic pemphigus: report of a case and review of the literature. World J Surg Oncol., 2007- 28(5):45.
- Mentink LF, Mackenzie MW, Toth GG et al. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: pemplus trial. Arch Dermatol., 2006- 142(5): 570−6.
- Mentink LF, de Jong MC, Kloosterhuis GJ Coexistence of IgA antibodies to desmogleins 1 and 3 in pemphigus vulgaris, pemphigus foliaceus and paraneoplastic pemphigus. Br J Dermatol., 2007- 156(4): 635−41.
- Michailidou EZ, Belazi MA, Markopoulos AK, Tsatsos MI, Mourellou ON, Antoniades DZ. Epidemiologic survey of pemphigus vulgaris with oral manifestations in northern Greece: retrospective study of 129 patients. Int J' Dermatol., 2007- 46(4): 356−61.
- Miida H, Kazama T, Inomata N et al. Severe gastrointestinal involvement in paraneoplastic pemphigus. Eur J Dermatol., 2006- 16(4): 420−2.
- Mimouni D, Nousari CH, Cummins DL et al. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol., 2003- 49: 1059−62.
- Mittmann Chan B, Knowles S, Mydlarski PR. Effect of intravenous immunoglobulin on prednisone dose in patients with pemphigus vulgaris. J Cutan Med Surg., 2006- 10(5): 222−7.
- Miyagawa S, Niizeki H, Yamashina Y, Kaneshige T. Genotyping for HLA-A, B and G alleles in Japanese patients with pemphigus: prevalence of Asian alleles of the 1-ILA-B15 family. Br J Dermatol. 2002- 146: 52−8.
- Murrell D. F. Consensus statement on definitions of disease, endpoints, and. therapeutic response for pemphigus. Abstract from CD. J Eur Acad Dermatol Venereol., 2008- SSP02.3.
- Mutasim D.F., Pclc N.J., Anhalt G.T. Paraneoplastic pemphigus. Dermatol. Clin., 1993- 11:473−481.
- Mutasim DF, Bilic M, Hawayek LH et al. Immunobullous diseases. J Am Acad Dermatol. 2005- 52: 1029−43.
- Nair PS. Moorthy PK, Yogiragan K. A study of mortality in dermatology. Indian J Dermatol Venereol LeproL, 2005- 71(1): 23−5.
- Nambiar MP., Enycdy EJ., Fisher CU. et al. Dexametasone modulates TCR zeta chain expression and antigen receptor-mediated early signaling events in human T lymphocytes. Cell Immunol., 2001- 208(1): 62−71.
- Nanda M, Nanda A, Al-Sabah II et al. Paraneoplastic pemphigus in association with. B-cell lymphocytic leukemia and hepatitis C: favorable response to intravenous immunoglobulins and prednisolone. Iht J Dermatol. 2007- 46(7): 767−769.
- Nast A., Kopp I., Augustin M., Banditt KB. Et all. German evidence based guidelines for treatment of psoriasis vulgaris (short version). Arch Dermatol Res., 2007- 299: 111−138.
- Niedermeier A, Worl P, Barth S, Schuler G, Hertl M. Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur J Dermatol., 2006- 16(3): 266−70.
- Nikolskaia OV, Nousari CH, Anhalt GJ. Paraneoplastic pemphigus in association with Castleman’s disease. Br J Dermatol., 2003- 149(6): 1143−51.
- Parlowsky T, Welzel J, Amagai M. et al. Neonatal pemphigus vulgaris: IgG4 autoantibodies to desmoglein 3 induce skin blisters in newborns. J Am Acad Dermatol., 2003- 48: 623−625.
- Pereira CM, Gasparetto PF, Aires MP. Pemphigus vulgaris in a juvenile patient: case report. Gen Dent., 2006- 54(4): 262−4.
- Perry HO, Brunsting LA. Pemphigus foliaceus. Arch Dermatol., 1965- 91: 10−23.
- Pfutze M., Neidermeier A., Hertl M. Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J Dermatol., 2007- 17 (1): 4−11.
- Pitarch G, Sanchez-Carazo JL, Pardo J, Torrijos A, Roche E, Fortea JM. Treatment of severe refractory pemphigus vulgaris with rituximab. [Article in Spanish], Actas Dermosifiliogr., 2006- 97(1): 48−51.
- Preisz K, Karpati S. Paraneoplastic pemphigus. [Article in Hungarian]. Orv Hetil., 2007- 148(21): 979−83.
- Radzikowska E, Pawlowski J, Chabowski M et al. Constrictive bronchiolitis obliterans in patient with Castelman’s disease. Monaldi Arch Chest Dis., 2005- 63(4): 226−9.
- Rao PN, Lakshmi TS. Pulse therapy and its modifications in pemphigus: a six year study. Indian J Dermatol Venereol Leprol., 2003- 69(5): 329−33.
- Reddy IS, Swarnalata G. Fatal disseminated strongyloidiasis in patients on immunosuppressive therapy: report of two cases. Indian J Dermatol Venereol Leprol., 2005- 71(1): 38−40.
- Reich K., Brinck U., Letschart M. et al. Graft-versus host disease like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus. Br J Dermatol, 1999- 141: 73946.
- Rico MJ, Benning C, Weingart ES, Streilein RD, Hall RP III. Br. J. Dermatol, 1999- 140(6): 1079−86:
- Robak E, Robak T. Skin lesions in chronic lymphocytic leukemia. Leuk Lymphoma., 2007- 48(5): 855−65.
- Robinson N.D., Hashimoto T., Amagai Ml, Chan L.S. et al. The new pemphigus variants J. Acad, of Dermatol, 1999- 4(5): 649−671.
- Saenz-Cantele AM, Fernandez-Mestre M- MontagnanL S et al. HLA-DRB 1*0402' haplotypes without DQB 1*0302 in Venezuelan patients with' pemphigus vulgaris. Tissue Antigens., 2007- 69(4): 318−25.
- Sanchez-Perez J, Garcia-Diez A. Pemphigus. [Article in Spanish]. Actas Dermosifiliogr., 2005- 96(6): 329−56.
- Santi CG, Flores RS, Medina MM et al. Paraneoplastic pemphigus associated with pelvic inflammatory fibrosarcoma: a case report. J Dermatol., 2005- 32(12): 1014−20.
- Sarma N, Ghoch S. Mycophenolate mofetil as adjuvant in pemphigus vulgaris. Indian J Dermatol Venereol Leprol., 2007- 348−50.
- Savin JA. The events leading to death of patients with pemphigus and pemphigoid. Br J dermatol., 1979- 101: 521−534.
- Scheinfeld N. A review of rituximab in cutaneous medicine. Dermatol Online J., 2006- 12(1): 3. :
- Schmidt E, Brocker EB, Zillikcns D. Pemphigus. Loss of desmosomal cell-cell contact. [Article in German]. Hautarzt, 2000- 51(5):. 309−18. '¦ • '¦.'¦'•., ¦ ' -'.
- Schmidt E, Hunzelmann N, Zillikens D, Brocker EB, Goebeler M. Rituximab inrefractory autoimmune bullous diseases. Clin Exp Dermatol., 2006- 31(4), 503.8. ¦ =
- Schmidt E, Seitz CS, Benoit S et al. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol-, 2007- 156(2):352.6.' «¦. ¦
- Segura S, Iranzo P, Martinez-de Pablo I, .Mascaro JM et al. High-dose intravenous immunoglobulins for the treatment of autoimmune, mucocutaneous blistering diseases: evaluation of its use in 19 cases. J Am Acad Dermatol., 2007- 56(6): 960−7.
- Shahidi-Dadras M, Karami A, Toosy P, Shafiyan A. Pulse versus oral — methylprednisolone therapy in pemphigus vulgaris. Arch- Iran Med., 2007−10(1): 1−6.
- Shi BB, Li HZ, Rong S et al. Surgical diagnosis and treatment, of Castleman’s disease. [Article in Chinese]. Zhonghua Yi Xue Za Zhi., 2006- 86(3): 174−5.
- Shimanovich I, Herzog S, Schmidt E, Opitz A, Klinker E, Brocker EB, Goebeler M, Zillikens D. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol., 2006- 31(6): 768−74:
- Shimizu N, Yoshikawa N, Wada T, Handa H, Sano M, Fukuda K, Suematsu M, Sawai T, Morimoto C, Tanaka H. Tissue- and context-dependent modulation of hormonal sensitivity of glucocorticoid-responsive genes by HEXIMl Mol Endocrinol., 2008- 18: 236−241.
- Sitaru C, Zillikens D. Mechanisms of blister induction by autoantibodies. Exp Dermatol., 2005- 14: 861−875.
- Sitaru C., Mihai S., Zillikens D. The relevance of the IgG subclass of autoantibodies for blister. Induction in autoimmune bullous skin diseases. Review article. Arch Dermatol Res., 2007- 299: 1−8.
- Spaeth S, Riechers R, Borradoru L. et al. IgG, IgA and IgE autoantibodies against the actodomain of desmoglein 3 in active pemphigus vulgaris. Br J Dermatol., 2001- 144(6): 1183−8.
- Spindler V, Drenckhahn D, Zillikens D et al. Pemphigus IgG Causes Skin ' Splitting in the Presence of Both Desmoglein 1 and Desmoglein 3. Am J Pathol. 2007 Jul 19- Epub ahead of print.
- Stanley J.R. Therapy of pemphigus vulgaris. Arch Dermatol 1999- 135 (1): 76−78.
- Stevens S.R., Griffiths C.E.M., Anhalt G.J., Cooper K.D. Paraneoplastic pemphigus presenting as a lichen planus pemphigoids-like eruption. Arch. Dermatol., 1993: 129: 866−869.
- Sundharam J. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Indian J Dermatol Venereol Leprol., 2006- 72(2): 173−4.
- Taintor AR, Leiferman KM, Hashimoto T et al. A novel case of IgA paraneoplastic pemphigus associated with chronic lymphocytic leukemia. J Am Acad Dermatol. 2007- 56(5 Suppl): 73−6.
- Tait A.S., Butts C.L., Sternberg E.M. Glucocorticoid and progesteron in disease susceptibility. Journal of Leukocyte Biology., 2008- 84: 1−8.
- Takahashi O, Okushiba S, Kondo S et al. Esophageal pemphigus vulgaris with carcinoma: postoperative steroid therapy based on pemphigus-related antibodies. Dis Esophagus., 2005- 18(6): 413−7.
- Tal A.K.E., Posner M.R., Spigelman Z. et all. Rituximab: A monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. J. AmAcad Dermatol., 2006- 55: 449−59
- Tamir A., Ophir J., Brenner S. Pemphigus vulgaris Triggered by Emotional Stress. Dermatology, 1994- 189−210.
- Tilakaratne W, Dissanayake M. Paraneoplastic pemphigus: a case report and review of literature. Oral Dis., 2005- 11(5): 326−9.
- Tirado-Sanchez A, Leon-Dorantes G. Paraneoplastic pemphigus associated with malignant fibrous histiocytoma. Int J Dermatol., 2006- 45(11): 1374−5.
- Torrelo A, Hashimoto T, Mediero IG et al. Pemphigus foliaceous in a child. Clin Exp Dermatol., 2006- 31(2): 288−9.
- Toto P., Feliciani C., Amerio P. et al. Immune modulation in pemphigus vulgaris: role of CD28 and IL-10. The Journal of Immunology, 2000- 164: 522−529.
- Uskiil B, Ertugrul M, Selvi A et al. A rare association: Castleman’s disease and pemphigus vulgaris. Tuberk Toraks., 2005- 53(2): 172−6.
- Uzun S, Durdu M. The specificity and sensitivity of Nikolskiy sign in the diagnosis of pemphigus. J Am Acad Dermatol., 2006- 54(3): 411−5.
- Van der Waal RI. Paraneoplastic pemphigus caused by an epithelioid leiomyosarcoma and associated with fatal respiratory failure. Oral Oncol., 2000- 36(4): 390−393.
- Van der Velden VH. Glucocorticoids: mechsnisms of action and antiinflammatory potential in asthma. Mediators inflamm., 1998- 7(4): 229−237.
- Veldman C., Stauber A., Wassmuth R. et al. Dichotomy of autoreactive TU1 and Th2 cell responses to desmoglein 3 in pqtients with pemphigus (PV) and healthy carries of PV-fssociated HLA Class II alleles. The Journal of Immunology., 2003- 170: 635−642.
- Vinson GP. The adrenal cortex and life. Mol Cell Endocrinol., 2008- 210 215.
- V’lckova-Laskoska MT, Laskoski DS et al. Epidemiology of pemphigus in Macedonia: a 15-year retrospective study (1990−2004). Int J Dermatol., 2007- 46(3): 253−8.
- Vojackova N, Hejcmanova I, Schmiedbergerova R, Hercogova J. Combined immunosuppressive therapy in patients with pemphigus vulgaris and its side effects. [Article in Czech]. Cas Lek Cesk., 2005- 144(12): 833−5.
- Walter H., S. Schepens J. Van Wauwe et al. Ligation of CD28 on resting T cells by its ligand B7 results in the production of both Thl- and Th2-type cytokines. Eur. Cytokine Network, 1994- 5:13-.
- Wang J, Bu DF, Li T et al. Autoantibody production from a thymoma and afollicular dendritic cell sarcoma associated with paraneoplastic pemphigus. Br J Dermatol., 2005- 153(3): 558−64.
- Wang J, Zhu X, Li R, Tu P et al. Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China. Arch Dermatol., 2005- 141(10): 1285−93.
- Waschke J, Menendez-Castro C, Bruggeman P et al. Imaging and Force Spectroscopy on Desmoglein 1 Using Atomic Force Microscopy Reveal Multivalent Ca (2+)-Dependent, Low-Affinity Trans-Interaction. J Membr Biol., 2007- Epub ahead of print.
- Weedon D. Skin pathology. Churchill Livingstone. P. 131−132.
- Whittock NV et al, Targetting of desmoglein 1 in inherited and acquired skin diseases. Clin. Exp. Dermatol., 2003- 28(4): 410−415.
- Wolff H., Kunte C., Messer G. et al. Paraneoplastic pemphigus with fetal pulmonary involvement in a women with mesenteric castelman tumor. British J. of Dermatol., 1999- 14 (2): 313−316.
- Yamamoto Y, Aoyama Y, Shu E et al. Anti-desmoglein 3 (Dsg3) monoclonal antibodies deplete desmosomes of Dsg3 and differ in their Dsg3-depleting activities related to pathogenicity. J Biol Chem., 2007- 282(24): 17 866−76.
- Yang M, Huang J, Pan HZ, Jin J. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells. Int J Mol Med., 2008- 22(4): 489−96.
- Yazganoglu KD, Baykal C, Ku9ukoglu R. Childhood pemphigus vulgaris: five cases in 16 years. J Dermatol., 2006- 33(12): 846−9.
- Yeh SW, Cavacini LA, Bhol KC, Lin MS, Kumar M, Duval M, Posner MR, Ahmed AR. Pathogenic human monoclonal antibody against desmoglein 3. Clin Immunol., 2006- 120: 68−75.
- Yokokura H, Demitsu T, Kakurai M et al. Paraneoplastic pemphigus mimicking erosive mucosal lichen planus associated with primary hepatocellular carcinoma. J Dermatol., 2006- 33(12): 842−5.
- Zillikens D, Arnbach A, Zentner A, Dummer R. Schussler M, Burg G, Brocker EB. Evidence for cell-mediated immune mechanisms in the pathology of pemphigus. Br J Dermatol., 1993- 128(6): 636−43.V307